HK1080847A1 - Stable hydrate of a muscarinic receptor antagonist - Google Patents

Stable hydrate of a muscarinic receptor antagonist

Info

Publication number
HK1080847A1
HK1080847A1 HK06100807A HK06100807A HK1080847A1 HK 1080847 A1 HK1080847 A1 HK 1080847A1 HK 06100807 A HK06100807 A HK 06100807A HK 06100807 A HK06100807 A HK 06100807A HK 1080847 A1 HK1080847 A1 HK 1080847A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonist
muscarinic receptor
stable hydrate
hydrate
stable
Prior art date
Application number
HK06100807A
Other languages
English (en)
Inventor
Dunn Peter James
Matthews John George
Newbury Trevor Jack
O'connor Garry
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1080847(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of HK1080847A1 publication Critical patent/HK1080847A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK06100807A 2002-03-26 2006-01-18 Stable hydrate of a muscarinic receptor antagonist HK1080847A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist
PCT/IB2003/001043 WO2003080599A1 (fr) 2002-03-26 2003-03-17 Hydrate stable d'antagoniste de recepteur muscarinique

Publications (1)

Publication Number Publication Date
HK1080847A1 true HK1080847A1 (en) 2006-05-04

Family

ID=9933731

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06100807A HK1080847A1 (en) 2002-03-26 2006-01-18 Stable hydrate of a muscarinic receptor antagonist
HK11111039.7A HK1156626A1 (en) 2002-03-26 2011-10-17 Stable hydrate of a muscarinic receptor antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11111039.7A HK1156626A1 (en) 2002-03-26 2011-10-17 Stable hydrate of a muscarinic receptor antagonist

Country Status (23)

Country Link
US (3) US6930188B2 (fr)
EP (2) EP1490357B1 (fr)
JP (2) JP2005524678A (fr)
KR (4) KR20120098888A (fr)
CN (1) CN100345840C (fr)
AR (1) AR042608A1 (fr)
AT (1) ATE495169T1 (fr)
AU (1) AU2003209921A1 (fr)
BR (2) BR122018000397B8 (fr)
CA (1) CA2480287C (fr)
CY (2) CY1111200T1 (fr)
DE (1) DE60335711D1 (fr)
DK (2) DK2336124T3 (fr)
ES (2) ES2358644T3 (fr)
GB (1) GB0207104D0 (fr)
HK (2) HK1080847A1 (fr)
PA (1) PA8569701A1 (fr)
PT (2) PT2336124E (fr)
SI (2) SI2336124T1 (fr)
SV (1) SV2003001515A (fr)
TW (1) TW200306816A (fr)
UY (1) UY27735A1 (fr)
WO (1) WO2003080599A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
GT200600162A (es) * 2005-04-24 2007-03-14 Metodos para modular la funcion de la vejiga
WO2007076158A2 (fr) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Procedes de preparation de bromhydrate de darifenacine
WO2008100651A2 (fr) * 2007-01-05 2008-08-21 Dr. Reddy's Laboratories Ltd. Préparation de darifénacine et ses sels
WO2008103426A1 (fr) * 2007-02-23 2008-08-28 Theravance, Inc. Composés de diphénylméthyle d'ammonium quartenaire utilisés comme antagonistes de récepteur muscarinique
WO2008144602A1 (fr) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Dérivés de zamifénacine deutérés
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (fr) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOUVEAU PROCÉDÉ DE PRODUCTION D'HYDROBROMURE DE (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYL)ÉTHYL]-α.α -DIPHÉNYL-3-PYRROLIDINEACÉTAMIDE
CN101983187A (zh) 2008-04-02 2011-03-02 株式会社钟化 (s)-3-(1-氰基-1，1-二苯基甲基)吡咯烷的制备方法
WO2010032225A2 (fr) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Procédé de préparation de darifénacine et intermédiaires utilisés dans le cadre dudit procédé
EP2236509A1 (fr) 2009-04-01 2010-10-06 Ragactives, S.L. Méthode de préparation de dérivés de la pyrrolidine 1,3 substituée
WO2011070419A1 (fr) 2009-12-10 2011-06-16 Aurobindo Pharma Limited Procédé perfectionné pour la préparation de bromhydrate de darifénacine
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
MX2018007152A (es) * 2015-12-14 2018-08-15 Ironwood Pharmaceuticals Inc Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal.
US10384995B2 (en) * 2016-08-12 2019-08-20 Bayer Cropscience Aktiengesellschaft Method for preparing substituted styrene derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
JP2001502302A (ja) * 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
PT1490357E (pt) 2011-03-01
PA8569701A1 (es) 2003-12-10
DK2336124T3 (da) 2012-12-17
AR042608A1 (es) 2005-06-29
KR20040093477A (ko) 2004-11-05
US20050245597A1 (en) 2005-11-03
CN100345840C (zh) 2007-10-31
ES2358644T3 (es) 2011-05-12
KR20110130539A (ko) 2011-12-05
PT2336124E (pt) 2012-12-12
TW200306816A (en) 2003-12-01
UY27735A1 (es) 2003-10-31
BR122018000397B1 (pt) 2019-07-02
BR0308706A (pt) 2005-01-04
CN1642945A (zh) 2005-07-20
CA2480287C (fr) 2011-05-31
KR20100101182A (ko) 2010-09-16
CA2480287A1 (fr) 2003-10-02
BRPI0308706B8 (pt) 2021-05-25
AU2003209921A1 (en) 2003-10-08
CY1111200T1 (el) 2015-06-11
US20080167367A1 (en) 2008-07-10
BR122018000397B8 (pt) 2021-07-27
US20030191176A1 (en) 2003-10-09
US7696357B2 (en) 2010-04-13
HK1156626A1 (en) 2012-06-15
WO2003080599A1 (fr) 2003-10-02
CY1113433T1 (el) 2016-06-22
EP1490357A1 (fr) 2004-12-29
ATE495169T1 (de) 2011-01-15
BRPI0308706B1 (pt) 2018-07-10
SV2003001515A (es) 2003-12-15
SI2336124T1 (sl) 2012-12-31
EP1490357B1 (fr) 2011-01-12
EP2336124A1 (fr) 2011-06-22
KR20120098888A (ko) 2012-09-05
KR101212908B1 (ko) 2012-12-14
US6930188B2 (en) 2005-08-16
DE60335711D1 (de) 2011-02-24
EP2336124B1 (fr) 2012-08-29
JP2010195828A (ja) 2010-09-09
SI1490357T1 (sl) 2011-05-31
DK1490357T3 (da) 2011-04-04
GB0207104D0 (en) 2002-05-08
JP2005524678A (ja) 2005-08-18
KR101026283B1 (ko) 2011-03-31
ES2394067T3 (es) 2013-01-16

Similar Documents

Publication Publication Date Title
HK1156626A1 (en) Stable hydrate of a muscarinic receptor antagonist
AP1828A (en) Muscarinic Acetycholine receptor antagonists
HK1142322A1 (en) Diaryl ethers as opioid receptor antagonist
HK1073304A1 (en) Triazole derivatives as tachykinin receptor antagonists
ZA200510104B (en) Crystalline form of beta2 adrenergic receptor agonist
EP1553075A4 (fr) Antagonistes des recepteurs de l'acide lysophosphatidique (lpa)
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
HK1064100A1 (en) Adenosine a 2a receptor antagonists
IL158701A0 (en) Novel use of nk3 receptor antagonist
PL378753A1 (pl) Antagoniści receptora CCR-3
IL164016A0 (en) Azetidine derivatives as ccr-3 receptor antagonists
AU2003260072A8 (en) Antagonists of chemokine receptors
PL370799A1 (en) Aminotetralin derivatives as muscarinic receptor antagonists
AU2002356369A1 (en) Xanthine derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
SG131946A1 (en) Ccr3 receptor antagonists
GB0203412D0 (en) 5-HT 2B receptor antagonists
AU2003287219A8 (en) Il-8 receptor antagonists
AU2003249621A8 (en) Hemipteran muscarinic receptor
GB0218183D0 (en) A novel g protein-coupled receptor gave2
AU2002950373A0 (en) G protein-coupled receptor antagonists
AU2003236673A1 (en) G protein-coupled receptor variants
GB0203413D0 (en) 5-HT 2B receptor antagonists
HU0300988D0 (en) Combination containing antagonist of vanilloid receptor

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230316